Sareum is a clinical stage small molecule drug development company developing next generation kinase inhibitors for autoimmune disease and cancer. Our strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering.
Our pipeline is centred around the TYK/JAK cell signalling family, which is important for maintaining a healthy immune system. The JAK cell signalling family is an area of growing scientific and commercial focus.
Sareum’s most advanced internal programme is SDC-1801, a potent and selective TYK2/JAK1 inhibitor, targeting autoimmune disease, with psoriasis a focus.
Our strategy is to develop programmes to late preclinical or early clinical stages before licensing or partnering. Led by a highly experienced team, with expertise in kinase inhibition and decades of experience in R&D, we maintain a lean cost base with a small team, and use trusted third party providers to maximise return on investment.
Sareum also has an economic interest in SRA737, a clinical-stage, oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.